Intellectual Property

To ensure the comprehensive protection of our efforts and opportunities, we have implemented—and are continuing to enhance—a multi-level patent strategy safeguarding our pulsatile dosing approach. The first level of “umbrella” patents is designed to protect the pulsatile delivery of general classes of drugs such as antibiotics or antivirals. “Sub-umbrella” patents comprise the second level, addressing subclasses of drugs like beta-lactam antibiotics. The third level of patents applies to specific pulsatile drugs.

This range of patents covers current and future innovations surrounding our intellectual property, including routes of administration, drug delivery technologies, and enhancements. MiddleBrook currently owns 26 issued and allowed U.S. patents and two foreign patents.